247 related articles for article (PubMed ID: 37906356)
1. Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis.
Brown R
Curr Oncol Rep; 2023 Dec; 25(12):1409-1417. PubMed ID: 37906356
[TBL] [Abstract][Full Text] [Related]
2. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
3. Available Therapies for Patients with Neurofibromatosis-Related Nervous System Tumors.
Strowd RE
Curr Treat Options Oncol; 2020 Aug; 21(10):81. PubMed ID: 32767156
[TBL] [Abstract][Full Text] [Related]
4. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E
Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
Friedrich RE; Beer C; Glatzel M; Hagel C
Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
[TBL] [Abstract][Full Text] [Related]
6. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
Acar S; Armstrong AE; Hirbe AC
Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
[TBL] [Abstract][Full Text] [Related]
7. Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018-2019.
Collins-Sawaragi YC; Ferner R; Vassallo G; De Agrò G; Eccles S; Cadwgan J; Hargrave D; Hupton E; Eelloo J; Lunt L; Tang V; Burkitt Wright E; Lascelles K
Am J Med Genet A; 2022 Jun; 188(6):1723-1727. PubMed ID: 35178860
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review of Recent and Ongoing Clinical Trials in Patients With the Neurofibromatoses.
Acar S; Nieblas-Bedolla E; Armstrong AE; Hirbe AC
Pediatr Neurol; 2022 Sep; 134():1-6. PubMed ID: 35759947
[TBL] [Abstract][Full Text] [Related]
10. Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
Gross AM; Dombi E; Widemann BC
Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696
[TBL] [Abstract][Full Text] [Related]
11. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study.
Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I
Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501
[TBL] [Abstract][Full Text] [Related]
12. The Diagnosis and Management of Neurofibromatosis Type 1.
Ly KI; Blakeley JO
Med Clin North Am; 2019 Nov; 103(6):1035-1054. PubMed ID: 31582003
[TBL] [Abstract][Full Text] [Related]
13. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
14. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Anderson MK; Johnson M; Thornburg L; Halford Z
Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Pathology of Tumors of Peripheral Nerve.
Belakhoua SM; Rodriguez FJ
Neurosurgery; 2021 Feb; 88(3):443-456. PubMed ID: 33588442
[TBL] [Abstract][Full Text] [Related]
16. Plexiform Neurofibroma Without Neurofibromatosis Type 1.
Wollina U; Schönlebe J
Acta Dermatovenerol Croat; 2020 Dec; 28(7):245-246. PubMed ID: 33835000
[TBL] [Abstract][Full Text] [Related]
17. Management of neurofibromatosis type 1-associated plexiform neurofibromas.
Fisher MJ; Blakeley JO; Weiss BD; Dombi E; Ahlawat S; Akshintala S; Belzberg AJ; Bornhorst M; Bredella MA; Cai W; Ferner RE; Gross AM; Harris GJ; Listernick R; Ly I; Martin S; Mautner VF; Salamon JM; Salerno KE; Spinner RJ; Staedtke V; Ullrich NJ; Upadhyaya M; Wolters PL; Yohay K; Widemann BC
Neuro Oncol; 2022 Nov; 24(11):1827-1844. PubMed ID: 35657359
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
de Blank PMK; Gross AM; Akshintala S; Blakeley JO; Bollag G; Cannon A; Dombi E; Fangusaro J; Gelb BD; Hargrave D; Kim A; Klesse LJ; Loh M; Martin S; Moertel C; Packer R; Payne JM; Rauen KA; Rios JJ; Robison N; Schorry EK; Shannon K; Stevenson DA; Stieglitz E; Ullrich NJ; Walsh KS; Weiss BD; Wolters PL; Yohay K; Yohe ME; Widemann BC; Fisher MJ
Neuro Oncol; 2022 Nov; 24(11):1845-1856. PubMed ID: 35788692
[TBL] [Abstract][Full Text] [Related]
19. Methylation-based classification of benign and malignant peripheral nerve sheath tumors.
Röhrich M; Koelsche C; Schrimpf D; Capper D; Sahm F; Kratz A; Reuss J; Hovestadt V; Jones DT; Bewerunge-Hudler M; Becker A; Weis J; Mawrin C; Mittelbronn M; Perry A; Mautner VF; Mechtersheimer G; Hartmann C; Okuducu AF; Arp M; Seiz-Rosenhagen M; Hänggi D; Heim S; Paulus W; Schittenhelm J; Ahmadi R; Herold-Mende C; Unterberg A; Pfister SM; von Deimling A; Reuss DE
Acta Neuropathol; 2016 Jun; 131(6):877-87. PubMed ID: 26857854
[TBL] [Abstract][Full Text] [Related]
20. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.
Carrió M; Gel B; Terribas E; Zucchiatti AC; Moliné T; Rosas I; Teulé Á; Ramón Y Cajal S; López-Gutiérrez JC; Blanco I; Castellanos E; Lázaro C; Stemmer-Rachamimov A; Romagosa C; Serra E
Hum Mutat; 2018 Aug; 39(8):1112-1125. PubMed ID: 29774626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]